Dr. Patrick Baeuerle argues the biggest challenge for cell engagers and CAR-T therapies is not killing power but the tumor's ability to down-regulate or lose the target antigen. This heterogeneity is a fundamental escape mechanism that future multi-targeting strategies must address to prevent relapse.

The success of early CAR-T cell therapies was partly luck. Future therapies face a high bar, as an ideal target must meet three criteria: 1) be abundant on cancer cells, 2) be indispensable for the cancer's survival, and 3) be dispensable for the patient's healthy tissues to avoid lethal toxicity.

The failure of immunotherapies like BiTEs in extramedullary sites (e.g., pleura, small bowel) is not just a drug delivery problem. These tissue microenvironments contain immuno-regulatory influences that actively suppress T-cell engagement and function, creating a biological barrier to effective treatment.

Unlike immune cells engineered to kill tumors (e.g., CAR-T), Mesenchymal Stem Cells (MSCs) solve a different problem. Their primary role is to leverage natural trafficking ability to reach the tumor microenvironment and deliver therapeutic payloads, rather than acting as immune effectors themselves.

An innovative strategy for solid tumors involves using bispecific T-cell engagers to target the tumor stroma—the protective fibrotic tissue surrounding the tumor. This novel approach aims to first eliminate this physical barrier, making the cancer cells themselves more vulnerable to subsequent immune attack.

Developing CAR T-cell therapies for solid tumors is difficult because many tumor-associated antigens are also expressed on normal tissues. This creates a significant risk of "on-target, off-tumor" effects, causing severe toxicity. Mitigating this risk, for instance with engineered "kill switches," is as crucial as preserving the therapy's efficacy.

Instead of focusing solely on T-cells, Create's platform first targets myeloid cells, which constitute up to 60% of some solid tumors. Programming these cells transforms the tumor microenvironment, enabling a 5-10x influx of CD8 T-cells. This overcomes a key barrier for T-cell therapies in solid tumors.

CAR-T cells are engineered to recognize a single antigen, which tumors can downregulate to escape. In contrast, TIL therapy uses a patient's own T-cells that naturally recognize multiple tumor antigens. This polyclonal attack creates a higher barrier for the cancer to develop resistance compared to a single-target CAR-T therapy.

Rather than expecting cell therapies (CAR-T, TIL) to eradicate every cancer cell, Dr. Radvanyi reframes them as powerful adjuvants. Their role is to inflict initial damage, kill tumor cells, and release antigens, creating an opportunity to prime a broader, secondary immune response with other modalities like vaccines or checkpoint inhibitors.